上海康岱生物医药技术

Condat Biopharmaceutical is a clinical-stage biotechnology company based in Shanghai, China, dedicated to the discovery and development of innovative small molecule therapeutics for oncology and autoimmune diseases. The company leverages a proprietary structure-based drug design (SBDD) platform to target challenging proteins within the MAPK signaling pathway, such as SHP2 and KRAS. Its lead candidate, CD-001, is a potent and selective SHP2 inhibitor currently undergoing Phase 1 clinical trials for the treatment of advanced solid tumors. Founded by industry veterans with extensive experience at global pharmaceutical firms like Novartis and Amgen, Condat Bio is supported by leading venture capital investors including Qiming Venture Partners and TF Capital. The company's research strategy focuses on precision medicine to address significant unmet needs in the global oncology market.